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Abstract. The objective of the present paper was the development and the full characterization of
antifungal films. Econazole nitrate (ECN) was loaded in a polymeric matrix formed by chitosan (CH)
and carbopol 971NF (CB). Polyethylene glycol 400 and sorbitol were used as plasticizing agents. The
mechanical properties of films were poorer when the drug was loaded, probably because crystals of ENC
produces network outages and therefore reduces the polymeric interactions between the polymers.
Polymers–ECN and CH–CB interactions were analyzed by Fourier-transform infrared spectroscopy
(FTIR), thermal gravimetry analysis, and differential thermal analysis (DTA-TGA). ECN did not show
structure alterations when loaded into the films. In scanning electron microphotographs and atomic force
microscopy analysis, films prepared with CB showed an evident wrinkle pattern probably due to the
strong interactions between the polymers, which were observed by FTIR and DTA-TGA. The in vitro
activity of the formulations against Candida krusei and Candida parapsilosis was twice as greater as the
commercial cream, probably as a result of the antifungal combination of the drug with the CH activity. All
these results suggest that these polymeric films containing ECN are potential candidates in view of
alternatives dosages forms for the treatment of the yeast assayed.
KEY WORDS: anti-fungal activity; drug delivery systems; in vitro models; infrared spectroscopy;
thermogravimetric analysis.
INTRODUCTION
Chitosan (CH), a cationic biocompatible and biodegrad-
able biopolymer used for biomedical applications is a polysac-
charide derived from chitin (1). This polymer obtained mainly
by extraction from crustacean shells such as crab and shrimp,
has been used in diverse fields, such as seed coating, as fuel
cell membranes, controlled drug delivery systems, membrane-
based transdermal drug delivery systems, wound healing,
dressing material, and tissue engineering (1–5). Depending
on its application, CH can be formulated as microparticles or
nanoparticles, powders, hydrogels, or films (6–8). Specifically,
films based on CH have been mainly developed for food
packaging (9), or for pharmaceutical applications. In the latter
case, different administration routes and uses such as buccal
delivery of flufenamic (10), control release of amoxicillin in
stomach for the treatment of Helicobacter pylori (11), vaginal
delivery of metronidazole for the treatment of bacterial vagi-
nosis (12), or potential skin drug delivery systems (13) were
evaluated. Several works have studied the mechanical prop-
erties of CH films, demonstrating that these properties may be
improved when CH forms polyelectrolyte complexes with
other polymers oppositely charged (14,15). Carbopol 971NF
(CB) is a useful polymer which may be anionic, depending on
the pH value, and therefore it may generate ionic interactions
with CH. This polymer is frequently employed as a major
component of drug delivery gel systems for buccal, transder-
mic, ocular, rectal, and nasal applications (16). Thus, the in-
teraction between the polymers may produce a polymeric
matrix which could be able to transport and release different
drugs. Antifungal agents are interesting drugs to be used as
model due to, among the different microbes that affect the
quality of life of the entire population, infectious diseases
caused by human pathogenic fungi represent a major and
global health problem (17). Aside from fungi, the opportunis-
tic yeasts are acquiring major importance due to the increase
of extremely aged persons, patients in intensive care units, and
the use of antibiotics and immunosuppressive agents (18).
Additionally, the advances in medical management as anti-
neoplasic chemotherapy, organ transplantation, parenteral nu-
trition, invasive surgical procedures, and the human
immunodeficiency virus infection, allowed a continuous
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growth of Candida-associated diseases (19,20). Among them,
Candida parapsilopsis is able to cause infections of the human
skin, the mucosa, and the viscera, while the less virulent
Candida krusei causes nosocomial infections (21). On the
other hand, vaginal yeast infections are one of the most com-
mon reasons of women seeking healthcare, and it has been
estimated that 70–75% of women will have an episode of
Candida vaginitis at least once during their lifetime (22). Sev-
eral drugs are used to treat these pathologies, between them,
econazole nitrate (ECN), an imidazole antifungal agent, is
mostly administered topically for the treatment of skin infec-
tions and vaginal candidiasis (23). Particularly, vaginal deliv-
ery is an important route of drug administration for both local
and systemic diseases. The vaginal route appears to be highly
appropriate for bioadhesive drug delivery systems in order to
retain drugs for treating largely local conditions (24). Conse-
quently, and due to the reported mucoadhesive properties of
both CH and CB (25–27), the development of films based on
these polymers and loaded with ECN may be adequate for a
potential vaginal administration. Therefore, the aims of the
present work were: (1) to develop polymeric films loaded with
ECN as model drug, (2) to evaluate their mechanical proper-
ties, interactions between the components and microscopic
morphology, and (3) to investigate if the matrix is able to
release the drug and compare the in vitro antifungal activity
of the films versus an antifungal commercial cream.
MATERIALS AND METHODS
Materials
Chitosan (230 KDa average molecular weight and 80.6%
of N-deacetylation) was supplied by Aldrich Chemical Co.
(Milwaukee, WI, USA), carbomer (Carbopol ® 971NF) by
Lubrizol Advanced Materials, Inc. (Cleveland, OH, USA),
and econazole nitrate pharmaceutical grade, by Parafarm,
(Buenos Aires, Argentina). All other chemicals were of ana-
lytical grade.
Methods
Preparation of the Films
Chitosan solutions (1% w/v) were prepared by dispersing
CH in aqueous lactic acid solution (2% v/v) and stirring over-
night (28). CB solutions (1% w/v) were prepared by dissolving
in water. The pH of the solutions was adjusted at 1 by addition
of 1 M HCl, in order to avoid precipitation when mixing the
solutions of the polymers (13,29). Both CH and CB solutions
were filtered through Miracloth® (Calbiochem-Novabiochem
Corp., San Diego, CA) to remove impurities prior to use. The
CH solutions were dripped to the CB solutions and mixed
with a mechanical stirrer during 5 min. Then sorbitol (S) or
polyethyleneglycol 400 (PEG 400) 20% and ECN powder at
1% w/w (previously blended through a 10-μm filter) were
added (Table I summarizes the films compositions, working
conditions, and the coding used). The mixture was stirred at
200 rpm during 2 h in a magnetic Boecco stirrer (Germany).
The solutions were then cast on Petri dishes (10 cm in diam-
eter) and dried in an oven at 25°C, constant RH (58%). After
drying, films were neutralized in casting by addition of NaOH
solution 5% (w/v), washed with distilled water, and dried
again (30,31). Dried films were removed from the plates and
conditioned in a chamber (25°C and 58% RH) for 3 days. The
films used in the different tests were selected based on the lack
of physical defects such as cracks, bubbles, and holes.
Film Thickness
Film thickness was measured with a digital micrometer
(Schwyz, China). For each film, ten thickness measurements
were made. Averaged values of thickness measurements were
calculated and used in all calculations.
Mechanical Properties
Mechanical strengths of the films were evaluated using a
Universal Testing Machine Instron, single column, Series 3340
(Instron, Norwood, MA, United States) with a 10-N load cell.
Eight replicate measurements were performed by each me-
chanical test. Probes for each mechanical test were condi-
tioned for 1 day at 25°C and 58% RH and equilibrated to
the testing environment for 2 h at 22°C and 50% RH on
average. In the puncture test, films (90 mm diameter) were
fixed to a support with a circular opening, and a cylindrical
probe (2 mm diameter) was moved perpendicularly to the film
surface at a constant speed (0.8 mm/s) until the probe passed
through the film. Force–deformation curves were obtained.
Force (Newtons) and deformation (millimeters) values at the
puncture point were then recorded to represent the puncture
strength (PS) and deformation (D) of the films (32). To eval-
uate tensile properties, films were cut into strips (7 mm wide
and 60 mm length) using a scalpel. The strip ends were
mounted with double-sided tape and squares of 30 mm of
cardstock (to prevent tearing and slippage in the testing de-
vice) (33). Between cardstock ends, the exposed film strip
length was 30 mm. The initial grip distance was 30 mm and
the crosshead speed was 0.05 mm/s. The parameters obtained
from stress–strain curves were: tensile strength (TS), calculat-
ed by dividing the peak load by the cross-sectional area (thick-
ness of film) of the initial film, and elongation (E), calculated
as the percentile of the change in the length of specimen
respect to the original distance between the grips (30 mm).
Table I. Summarizes the Films Compositions, Working Conditions,
and the Coding Used in What Follows
Formulation CH (%) CB (%) PEG 400 (%) S (%) ECN (% w/w)
FI 100 0 2 – 0
FII 100 0 2 – 1
FIII 100 0 – 2 0
FIV 100 0 – 2 1
FV 90 10 2 – 0
FVI 90 10 2 – 1
FVII 90 10 – 2 0
FVIII 90 10 – 2 1
FIX 80 20 2 – 0
FX 80 20 2 – 1
FXI 80 20 – 2 0
FXII 80 20 – 2 1
65Design and Evaluation of Antifungal Polymeric Films
Fourier Transform Infrared Spectroscopy
Fourier transform infrared (FT-IR) spectra were
obtained by an FT-IR-Prestige-21 (Shimadzu, Tokyo, Japan)
using the KBr disk method (2 mg sample in 100 mg KBr).
Scanning range was 450 to 3,900 cm−1 with a resolution of
1 cm−1.
Thermal Gravimetric Analysis and Differential Thermal
Analysis
The films, the polymers, and ECN were investigated by
thermal gravimetry analysis and differential thermal analysis
(TGA-DTA) methods, using equipment having a high sensi-
tive weight balance (Shimadzu DTG60). Samples of approxi-
mately 20 mg, consisting in drug, polymers powder, or pieces
of films, were heated at a rate of 10°C/min up to 700°C. All
curves were normalized to unity of the initial sample mass.
Scanning Electron Microscopy
The morphology of the films was investigated by scanning
electron microscopy (SEM) using an AMR 1000 Scanning
Microscope (Amray, Bedford, MA). Films were mounted on
an aluminum sample support by means of a conductive and
double-sided adhesive. Samples were previously sputter coat-
ed with a gold layer in order to make them conductive.
Atomic Force Microscopy
Atomic force microscopy (AFM) images were obtained
using a NanoTec Electronica AFM equipment. All images
were obtained on contact mode and at a scan rate of 2 Hz.
The 3D surfaces and rugosity distribution were analyzed
employing WSxM 4.0 betha 5.0 software (34).
Water Uptake. In order to obtain a full characterization of
the matrix, the affinity of the systems by water was deter-
mined. Each film was soaked in 200 ml of citrate buffer
pH 4.2 or phosphate buffer pH 7.2 at 37°C. To estimate the
amount of water absorbed at different times, the systems were
taken out, carefully wiping off excess of medium and quickly
weighed, then the samples were placed back in water.
The water uptake percentage was calculated according to
the following equation:
Water uptake ¼ FsFdð Þ Fd 100%;=
where Fs 0mass of the swollen film and Fd 0mass of the dry film.
Dissolution Studies
Dissolution studies of ECN from the matrices were per-
formed in 900 ml of either in citrate buffer (pH 4.2) or in
phosphate buffer (pH 7.2) at 37°C, using a USP XXIV appa-
ratus (Hanson Research, SR8 8-Flask Bath, Ontario, Canada)
with paddle rotating at 50 rpm. At different time intervals,
5 ml samples were withdrawn through a filter. The amount of
released ECN was determined by UV analysis at 270 nm. It
was found that the excipients did not interfere with the assay
at this wavelength. The results presented are mean values of
three determinations.
Halo Zone Test
Halo zone test was used to analyze the release of the anti-
fungal agent contained in the samples. A film of CH 100%
without drug and commercial cream (CC) containing the same
concentration of ECN were used as controls. CC (1% ECN and
excipients: stearic acid, cetilic alcohol, triethanolamine, PEG
400, sorbitol, and propylparben) was lean on a 5-mm round
aluminum disk which was used as support of the cream. The in
vitro activity of the films were evaluated by the diffusionmethod
in an agar Müeller Hinton medium, using C. krusei (ATCC
6258) and Candida parapsilosis (ATCC 22019) as yeast for the
tests. The films were taken, cut into 5 mm round films, and
leaned (with the controls) in Petri dishes that were incubated
at 37°C. The anti-fungal activity of the films on the plate was
determined according to the size of the inhibitory zone at a fixed
time. The assay was developed by triplicate (35).
Stability Study
Representative samples were placed in a controlled tem-
perature cabinet at 25°C or 40°C and 58% RH (36). Monthly,
films were dissolved by magnetic stirred in citrate buffer,
900 ml (pH 4.2) for 48 h at 37°C, then the solutions were
filtered through 0.20-μm membrane filter. The amount of
ECN release was analyzed by UV at 270 nm.
Statistical Analysis
Results are expressed as mean ± standard error. Analysis
of variance was used and when the effect of the factors was
significant (p<0.05), the Tukey multiple ranks honestly signif-
icant difference test was applied (95% of confidence level).
RESULTS AND DISCUSSION
ECN Films Characterization
Mechanical Properties
As can be observed in Fig. 1, the thickness of the
films was not affected by the parameters analyzed, not
showing significant differences between the formulations
even when the films were loaded with ECN (p>0.05). In
the formulations without drug, the effect of sorbitol (S)
was evident over PS, deformation, TS, and E, producing
more elastic and flexible films, with better mechanical
properties than those containing PEG 400 in the matrix.
This is probably because S could act by the same mech-
anism of glycerol as internal plasticizer, penetrating
through the polymer matrix and interfering with CH
chains, decreasing intermolecular attraction and increasing
polymer mobility, which led films to be more flexible. In
contrast, PEG 400 acts as an external plasticizer (37)
producing films with poor mechanical properties. This fact
could be explained due to the fact that crystalline struc-
tures of polymeric materials are stabilized by second-order
bonds, which are destroyed by plasticizers, modifying the
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mechanical properties of materials without altering their
fundamental chemical character. During external plastici-
zation, only weak second-order bonds develop between
the plasticizer and the polymer, while internal plasticizers
are covalently bound to the plasticized material. External
plasticizers can migrate in the polymer, which may lead to
recrystallization of the material and loss of elasticity (37).
The addition of ECN significantly decreased all the
parameters evaluated in tensile and puncture tests (p<0.05),
while no trend could be observed in relation with CB concen-
tration. These results could be attributed to the disruption of
the homo and hetero-polymeric interactions which are the
matrix former and the responsible of the mechanical proper-
ties. Such disruption of the matrix probably induces the de-
velopment of a heterogeneous film structure, resulting in a
decrease in both tensile strength and elongation. The mea-
surement of the mechanical properties of edible films is im-
portant because they are related to their durability, as well as
to the ability to resist the manipulation when they are applied
over zones affected by the pathology. Due to the fact that the
films with better mechanical properties (even when ECN was
loaded) were obtained employing S, the formulations contain-
ing this plasticizer were selected for further assays.
Fourier Transform Infrared Spectroscopy
FTIR spectra of pure ECN, CB, and CH powders and of
films FXI and FXII (20% CB with and without ECN) are
shown in Fig. 2. The characteristic bands of pure ENC are
observed at 1,585, 1,548, 828, 804, and 638 cm−1 (38). The CH
spectrum showed a broad band with a maximum at
3,440 cm−1, assigned to the stretching vibration of O–H and
N–H groups associated by intra- and intermolecular hydrogen
bonding. Absorption at 1,656 cm−1 (C0O stretching) and
1,599 cm−1 (N–H stretching) are characteristic of amide
groups. Finally, the broad band absorption at 1,090 cm−1 is
assigned to the overlapping of the bands at 1,049, 1,057, and
988 cm−1 assigned to CHs saccharide structure (39). In the CB
spectrum, formation of intramolecular hydrogen bonding can
be characterized by a broad band at 3,218 cm−1. The
absorption band at 1,708 cm−1 has been assigned to C0O
stretching vibration from carboxylic groups. The presence of
bands in the range of 1,500–1,150 cm−1 has been assigned to
C–O–C stretching vibrations. The films spectra were similar to
the CH spectrum, as expected, considering that the CH/CB
ratio used were 90:10 (data not shown) and 80:20, without and
with 1% of ECN (formulations FXI and FXII, respectively).
However, the peak at 1,599 cm−1 assigned to the amine
band of chitosan was shifted to 1,640 cm−1, indicating that the
NH2 group was protonated to a NH3
+ group in the films (40).
The bands at 1,550 and 1,408 cm−1 were assigned to the
symmetric and anti-symmetric stretching of the COO− group
(40,41). The broad peak around 1,550 cm−1 was believed to be
the overlapped peak of COO− and NH3
+ peaks, because the
NH3
+ peak appears between 1,600 and 1,460 cm−1 and in a
complex between CH and poly(acrylic acid) the NH3
+ peak
Fig. 1. Thickness (TH) of the films and parameters calculated from stress–strain (TS and E) and force-deformation curves (PS and D)
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appears at 1,520 cm−1. These results suggest that the CH/CB
film was formed by electrostatic interactions between the
COO− group of CB and the NH3+ group of CH (42). The
spectrum of formulation FXII containing ECN was similar,
and able to be overlapped to the formulation FXI without
drug. This is an indication of absence of interactions between
both polymers and ECN. This fact could be explained based
on intermolecular interactions which may occur when two
compounds are miscible. This will be reflected in changes of
the infrared spectra of the mixture, such as wavenumber shifts,
band broadening, and new absorption bans that are evidence
of the compounds miscibility. Because the drug was dispersed
as a solid form in the polymeric matrix during the film
formulation, polymers and drug were immiscible and
therefore it is expected that the resulting infrared spectrum
will be the sum of the spectra of the individual compounds
(43). Since the drug is only 1% of the formulation,
characteristic peaks of ECN are very weak by a dilution effect.
Thermal Gravimetric Analysis and Differential Thermal
Analysis
The thermal stability and the degradation behavior of pure
ECN, CB, and CHpowders and CH films with andwithout ECN
were studied by TGA-DTA under oxygen atmosphere. The TG
and DTA curves of the samples are shown in Fig. 3. Figure 3a
shows the TG curves of the starting materials: there was no
weight loss until ECN melting (162–166°C), while the loss of
ECN mass at 168°C could be attributed to the decomposition
of drug after melt (44). The CH powder presents a characteristic
chain degradation around 300°C and CB shows two peaks at 80°
C (water evaporation) and at 250–350°C, referred to a thermal
degradation at which CB melts and decomposes sequentially
(45). In films containing 100% CH without drug, three steps of
thermo-oxidative degradation were observed. The first one, in
the temperature range 60–120°C, was attributed to the loss of
absorbed water. The second one, at around 270°C, corresponds
to the chemical degradation and deacetylation of chitosan (46).
The third step, in the temperature range 450–600°C (data not
shown), can be associated with the oxidative degradation of the
carbonaceous residue formed during the second step. In films
containing CB, the water loss was observed at 40–150°C and its
degradation in the range 270–350°C. However, the mass loss
process in the temperature range studied is much more gradual
than the films containing 100% CH (FIV; Fig. 3b). When the
results of CH/CB are comparedwith the results of CH in terms of
the thermal behaviors, there are many important differences
which might be due to the interaction between CH and CB.
However, the characteristic peak of ENC appears unaltered in
the films loaded with drug (Fig. 3c). This fact demonstrates that
strong interactions between the matrix and the drug are absent.
Scanning Electron Microscopy
SEM of polymers, drug and surfaces and cross-sections of
the film membranes are shown in Fig. 4. The top views show
the polymers and ECN. While CH blocks of around 100 μm
present a smooth surface, CB and ECN appear as irregular
crystals of different sizes. Formulations FIV, FVIII, and FXII
show that all membranes are symmetric, uniformly distribut-
ed, and have a different morphology to wrinkles. It was also
possible to observe that such wrinkles became much more
evident on membranes with CB. Formulation FXII, which had
20% of CB, was the one in which a pattern of peaks and valleys
Fig. 2. FTIR spectra of pure ECN, CB and CH powders, and films FXI and FXII
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Fig. 4. Scanning electron microscopy of polymers (CH and CB), drug (ECN), and surfaces and cross-
sections of films membranes containing ECN and different amount of CH and CB
(FIV: CH 100%, CB 0%; FVIII: CH 90% CB 10%; and FXII: CH 80% CB 20%)
Fig. 3. Thermal stability and degradation behavior of pure ECN, CB, and CH powders and films loaded with
ECN; a and b thermal analysis, c differential thermal analysis
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wasmore pronounced, probably due to the higher occurrence of
interactions in this membrane because CB is present in higher
concentration and is able to form a larger number of electro-
static interactions and hydrogen bonds with CH.
Small crystals (probably of drug) can be observed over
the surface of the films, which could be another indication that
no interaction between polymers and ECN occurs.
Atomic Force Microscopy
The AFM images of the different formulations and their
rugosity distributions are shown in Fig. 5. As can be seen, 100%
CH films show an almost plane structure, with a rugosity distri-
bution around 500 nm. However, the peak and valley pattern
observed by SEM was notorious in films with CB (formulations
FVII, FVIII, FXI, and FXII). Such a pattern can be observed
over an extensive area of the membrane surface, showing a
distribution of rugosity around 1–1.3 μm for CB 10% and 2–
3.5 μm for CB 20%. Additionally, the films loaded with ECN
show incrustations (probably of drug) in the structure of the
matrix, which increase slightly the dispersion of the rugosity.
This peak and valley pattern is due to local variations on poly-
mer concentration causing a change on interfacial tension and
inducing additional convection at the interface (31,47).
Water Uptake
The water uptake profiles of the films are shown in
Fig. 6. When the assay was carried out in a solution pH 7.2
(Fig. 6a), FIV (100% CH) reaches its maximum of water
sorption at 120 min, after that time, reaches an equilibrium
state and no lost of weight was observed during the assay.
On the other hand, formulations FVIII (90% CH and 10%
CB) and FXII (80% CH and 10% CB) reach the maximum
water uptake at 60 min, after that, a diminished in the weigh
by erosion of the matrix was observed. This result could be
due to the films with CH and CB became more hydrophilic
than CH alone, producing strong polar sites, generating
better interactions between matrix and solvent and there-
fore producing faster water uptake (11,31). The loss of
weight observed in formulation FVIII and FXII could be
attributed to the partial solubilization of CB in the medium
pH 7.2 generating the erosion of the film. When the water
uptake was assayed in an acidic medium, the maximum
water uptake was allowed at 60 min and the weight loss
was evident in all three formulations. The mentioned effect
was more pronounced in FIV (100% CH). This result may
due to films are based on CH and this polymer is soluble in
acidic medium (Fig. 6b).
Fig. 5. Atomic force microscopy of surfaces films membranes with different content of CH and CB with ECN 1% (FIV: CH 100% CB 0%;
FVIII: CH 90% CB 10%; FXII: CH 80% CB 20%) and without ECN (FIII: CH 100% CB 0%; FVII: CH 90% CB 10%;
FXI: CH 80% CB 20%)
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Dissolution Assay
To obtain a complete characterization of the systems, the
release of ECN from FIV, FVIII, and FXII was evaluated at
two pH values (Fig. 6c, d). Although ECN is a poorly water-
soluble drug (48), it was solubilized faster than the drug load-
ed into the films, but, independently of the pH value, the ECN
dissolution profile was not significantly modified. When a
water-soluble drug is loaded into a CH matrix, there is an
initial burst effect in the early stage of the dissolution; this fact
is due to the disintegrative effect of the hydrophilic drug which
takes water rapidly by capillarity through available pores in
the matrix (49). After this initial hydration of the films, gel
formation of chitosan (pKa 6.5) in acid buffer medium
(pH 4.2) causes clogging of pores and thus hindering the
entrance of water. Therefore, drug is released from the films
by slow diffusion through the gel layer (50). However and due
to ECN is a hydrophobic poorly water-soluble drug, no signif-
icant differences were observed between the dissolution pro-
files at different pH values. After 6 h assay just 30% of ECN
was solubilized; this value is in good agreement with the one
found in the literature (51). Based on the obtained dissolution
profiles and in the results of water uptake assay, the release of
the drug from this polymeric matrix may be due to diffusion at
the beginning of the assay and then by a combination of
diffusion and erosion.
Fig. 6. Water uptake (a and b) and dissolution profiles (c and d) of films containing ECN and different
amount of CH and CB; a and c pH 7.2, b and d pH 4.2
Fig. 7. Halos of growth inhibition produced by films without ECN (FIII, FVII, FXI) and loaded
with ECN (FIV, FVIII, FXII) and a commercial cream (CC) in a culture of Candida krusei
71Design and Evaluation of Antifungal Polymeric Films
Halo Zone Test
Due to its importance in connection with the release and
activity of the drug loaded in the polymeric matrix, an anti-
fungal assay for the films was developed. Films without drug,
and a commercial cream containing the same content of ECN
were designed as controls. After a 24-h assay, the growth
inhibition of C. krusei was shown as dark areas around the
films (Fig. 7).
Similar areas were obtained for C. parapsilosis, indi-
cating no significant differences between the yeasts (p>
0.05). As can be observed, the three formulations assayed
produced similar 100% inhibition hales (9.0±1.0 mm) and
significant differences (p<0.05) with respect to the con-
trols (6.5±0.5 mm). Films without drug also showed an
inhibition zone (6.0±0.5 mm) that could be explained by
the previously reported antimicrobial activity of CH
(52–59), which generates a matrix with antifungal proper-
ties. Surprisingly, the halo zone of the commercial cream
(CC) containing an amount of ENC equal to that in the
films was half in diameter for the both yeast assayed. This
fact may probably be the result of the sum of the anti-
fungal activity of ECN and the “environmental and eco-
friendly” matrix. Therefore, it will be possible to produce
a new pharmaceutical form based on a polymeric film
containing ECN, which could be loaded with a small drug
concentration, and however produce the same therapeutic
effect against C. krusei and C. parapsilosis.
Stability Study
Stability studies carried out for formulations FIV, FVIII,
and FXII at 25°C, or 40°C and 58% RH revealed no signifi-
cant differences in drug content after a year. Mean drug
content for 1 year was above 98% at 25°C, and above 95%
at 40°C.
CONCLUSIONS
In this work, several formulations containing CH, CB,
and ECN were developed and studied. The application of
CH–CB films to load and release an antifungal drug was
demonstrated. The IR and ATD-TG analysis showed inter-
actions between the polymers. By SEM and AFM, drug
crystals over the films surface were observed. The rugosity
distribution of the systems was associated to the interac-
tions between polymers. The matrix was able to release the
drug in both neutral and acid medium probably by a
combination between drug diffusion and matrix erosion.
The in vitro antifungal activity was assayed against C.
krusei and C parapsilosis, showing the sum of antifungal
effects of ECN and CH, producing larger inhibition halos
than the same ECN concentration in a commercial cream.
Finally, formulations FIV, FVIII, and FXII containing S as
plasticizer and 1% ECN showed good mechanical proper-
ties and good antifungal activity. These formulations are
potential candidates for the development of alternatives
pharmaceutical form for the treatment of Candida, based
on the activity of the eco-friendly matrix added to the
econazole nitrate activity.
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